Plasma thymic stromal lymphopoietin (TSLP) in adults with non-severe asthma: the EGEA study - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Thorax Année : 2023

Plasma thymic stromal lymphopoietin (TSLP) in adults with non-severe asthma: the EGEA study

Résumé

Thymic stromal lymphopoietin (TSLP), a cytokine involved in severe asthma treatment, was never studied in non-severe asthma. Among 969 adults from a large epidemiological study, cross-sectional analyses showed that plasma TSLP levels were associated with increased age and BMI, male sex, smoking and high TSLP levels (one IQR increase) with current asthma and poor lung function. High TSLP levels were also associated with persistence of asthma attacks (aOR=2.14 (95% CI 1.23 to 3.72)) and dyspnoea (aOR=2.71 (95% CI 1.39 to 5.28)) 10 years later. Our results suggest that TSLP could be a cytokine of interest in non-severe asthma, and its determinants of circulating levels could be considered in asthma management.
Fichier non déposé

Dates et versions

hal-04302695 , version 1 (23-11-2023)

Identifiants

Citer

Bakari Ibrahim, Djamal Achour, Farid Zerimech, Patricia de Nadai, Valérie Siroux, et al.. Plasma thymic stromal lymphopoietin (TSLP) in adults with non-severe asthma: the EGEA study. Thorax, 2023, 78 (2), pp.207-210. ⟨10.1136/thorax-2022-219192⟩. ⟨hal-04302695⟩
14 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More